Richard James Mead

Richard James Mead

Auto-generated profile, based on publicly available information

Richard James Mead

Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MMMonika A. Myszczynska
Monika A. Myszczynska
POPoojitha N. Ojamies
Poojitha N. Ojamies
ALAlix M. B. Lacoste
Alix M. B. Lacoste
DNDaniel Neil
Daniel Neil
ASAmir Saffari
Amir Saffari
LFLaura Ferraiuolo
Laura Ferraiuolo

21 December 2022 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RMRichard J. Mead
Richard J. Mead
NSNing Shan
Ning Shan
HRH. Joseph Reiser
H. Joseph Reiser
FMFiona Marshall
Fiona Marshall
PSPamela Jean Shaw
Pamela Jean Shaw

1 November 2006 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SBSiân C. Barber
Siân C. Barber
RMRichard J. Mead
Richard J. Mead
PSPamela Jean Shaw
Pamela Jean Shaw

1 January 2010 in Amyotrophic Lateral Sclerosis
Verified
Journal Article
Open access
PDF file
ALA. C. Ludolph
A. C. Ludolph
CBCaterina Bendotti
Caterina Bendotti
EBEran Blaugrund
Eran Blaugrund
ACAdriano Chiò
Adriano Chiò
LGLinda Greensmith
Linda Greensmith
SHStephan von Hörsten
Stephan von Hörsten
The development of therapeutics for ALS/MND is largely based on work in experimental animals carrying human SOD mutations. However, translation of apparent therapeutic successes from in vivo to the human disease has proven difficult and a considerable amount of financial resources has been apparently wasted. Standard operating procedures (SOPs) for preclinical animal research in ALS/MND are urgently required. Such SOPs will help to establish SOPs for translational research for other neurological diseases within the next few years. To identify the challenges and to improve the research methodology, the European ALS/MND group held a meeting in 2006 and published guidelines in 2007 (1). A second international conference to improve the guidelines was held in 2009. These second and improved guidelines are dedicated to the memory of Sean F. Scott.

9 June 2010 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CVChiara F. Valori
Chiara F. Valori
KNKe Ning
Ke Ning
MWMatthew Wyles
Matthew Wyles
RMRichard J. Mead
Richard J. Mead
AGAndrew J. Grierson
Andrew J. Grierson
MAMimoun Azzouz
Mimoun Azzouz
Spinal muscular atrophy is one of the most common genetic causes of death in childhood, and there is currently no effective treatment. The disease is caused by mutations in the survival motor neuron gene. Gene therapy aimed at restoring the protein encoded by this gene is a rational therapeutic approach to ameliorate the disease phenotype. We previously reported that intramuscular delivery of a lentiviral vector expressing survival motor neuron increased the life expectancy of transgenic mice with spinal muscular atrophy. The marginal efficacy of this therapeutic approach, however, prompted us to explore different strategies for gene therapy delivery to motor neurons to achieve a more clinically relevant effect. Here, we report that a single injection of self-complementary adeno-associated virus serotype 9 expressing green fluorescent protein or of a codon-optimized version of the survival motor neuron protein into the facial vein 1 day after birth in mice carrying a defective survival motor neuron gene led to widespread gene transfer. Furthermore, this gene therapy resulted in a substantial extension of life span in these animals. These data demonstrate a significant increase in survival in a mouse model of spinal muscular atrophy and provide evidence for effective therapy.

19 March 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MWMatthew A. White
Matthew A. White
EKEosu Kim
Eosu Kim
ADAmanda Duffy
Amanda Duffy
RARobert Adalbert
Robert Adalbert
BPBenjamin U. Phillips
Benjamin U. Phillips
JSJemeen Sreedharan
Jemeen Sreedharan